VistaGen Therapeutics, Inc.
VTGN
$1.97
-$0.08-3.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 486.00K | 698.00K | 875.00K | 970.00K | 1.06M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 486.00K | 698.00K | 875.00K | 970.00K | 1.06M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 486.00K | 698.00K | 875.00K | 970.00K | 1.06M |
| SG&A Expenses | 17.08M | 16.93M | 16.64M | 15.65M | 14.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.46M | 53.54M | 46.48M | 39.12M | 34.08M |
| Operating Income | -55.97M | -52.84M | -45.60M | -38.15M | -33.02M |
| Income Before Tax | -51.41M | -47.30M | -39.56M | -33.19M | -29.36M |
| Income Tax Expenses | 7.00K | 8.00K | 8.00K | 1.00K | 4.00K |
| Earnings from Continuing Operations | -51.42 | -47.30 | -39.57 | -33.19 | -29.36 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.42M | -47.30M | -39.57M | -33.19M | -29.36M |
| EBIT | -55.97M | -52.84M | -45.60M | -38.15M | -33.02M |
| EBITDA | -55.82M | -52.69M | -45.47M | -38.03M | -32.89M |
| EPS Basic | -1.66 | -1.54 | -1.30 | -1.53 | -2.12 |
| Normalized Basic EPS | -1.04 | -0.97 | -0.81 | -0.96 | -1.33 |
| EPS Diluted | -1.66 | -1.54 | -1.30 | -1.53 | -2.12 |
| Normalized Diluted EPS | -1.04 | -0.97 | -0.81 | -0.96 | -1.33 |
| Average Basic Shares Outstanding | 123.51M | 122.47M | 121.14M | 100.55M | 77.29M |
| Average Diluted Shares Outstanding | 123.51M | 122.47M | 121.14M | 100.55M | 77.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |